Aravind S. Ravi Kumar

PSMA and FDG-PET as predictive and prognostic biomarkers in patients given [177Lu]Lu-PSMA-617 versus cabazitaxel for metastatic castration-resistant prostate cancer (TheraP): a biomarker analysis from a randomised, open-label, phase 2 trial

James P Buteau, Andrew Martin, Louise Emmett et al. · The Lancet Oncology · 2022 · 239 citations

Biomarker (Medicine), Prognostic Biomarkers, Urology +7

Prognostic biomarkers in men with metastatic castration-resistant prostate cancer receiving [177Lu]-PSMA-617

Justin Ferdinandus, John Violet, Shahneen Sandhu et al. · European Journal of Nuclear Medicine and Molecular Imaging · 2020 · 147 citations

Biomarker (Medicine), Prognostic Biomarkers, Urology +6

Characteristics and outcomes of therapy-related myeloid neoplasms after peptide receptor radionuclide/chemoradionuclide therapy (PRRT/PRCRT) for metastatic neuroendocrine neoplasia: a single-institution series

Isaac Goncalves, Kate Burbury, Michael Michael et al. · European Journal of Nuclear Medicine and Molecular Imaging · 2019 · 61 citations

Therapy-related Myeloid Neoplasms, Metastatic Neuroendocrine Neoplasia, Radiation Therapy +10

The segmental distribution and clinical significance of colorectal fluorodeoxyglucose uptake incidentally detected on PET-CT

Joseph C. Lee, Gemma F. Hartnett, Brett Hughes et al. · Nuclear Medicine Communications · 2009 · 54 citations

Overall survival and quality of life with [177Lu]Lu-PSMA-617 plus enzalutamide versus enzalutamide alone in metastatic castration-resistant prostate cancer (ENZA-p): secondary outcomes from a multicentre, open-label, randomised, phase 2 trial

Louise Emmett, Shalini Subramaniam, Megan Crumbaker et al. · The Lancet Oncology · 2025 · 39 citations

Urology, Oncology, Genitourinary Cancer +9